Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.
about
Post-exposure prophylaxis for SIV revisited: animal model for HIV preventionSafety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workersPotential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settingsVaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regenerationRole of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatmentYouth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.AIDS vaccines and preexposure prophylaxis: is synergy possible?Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxisCharacterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.Tenofovir resistance and resensitizationRT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models.CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.Efficient class I major histocompatibility complex down-regulation by simian immunodeficiency virus Nef is associated with a strong selective advantage in infected rhesus macaques.Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy.Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.SIV-specific T lymphocyte responses in PBMC and lymphoid tissues of SIV-infected pigtailed macaques during suppressive combination antiretroviral therapy.
P2860
Q21245029-5ECC695C-2D54-49E4-A894-36D32C3667C5Q21558500-B1CCD273-F4D6-4EC3-96D4-C48C8E4E0851Q33299456-CA0DC4E4-29FF-469F-9A77-405BEF1C684FQ33810277-3C2F3817-EBE5-466F-A63C-98A8A6514CA0Q33835422-A5D8C2D3-EA11-490D-A5D5-E22987E9E5B4Q33847673-779265FA-5922-4014-850B-79B62E714D93Q34030735-8C1DDD71-0B84-4BFB-B1DC-0B2AD4A2448DQ35003539-7034A4E9-1E7B-4AC5-A0CD-DC65794482D1Q35752812-7F53968E-793A-4954-9618-8E0C9AD42452Q36164175-A912926B-53A9-4E7E-97FC-4106F726A973Q36315555-9F25E1E2-2157-4B64-81D5-5AB8162B1BC1Q36379277-FC466880-EC16-4F78-9E33-35525FB155B9Q36389032-23234C1C-EDAC-4F4F-AD89-A626CC434C4FQ36879987-8CCCC3FF-82A6-422F-A0CD-B1FE606CC532Q37428359-1C113604-34EB-4C33-8F5F-C07B0D69611CQ37730097-4DF316BE-482A-496C-9DF4-5758549C73F2Q39604845-3055CA4B-83C1-4FA1-ADBC-41EFD64BC34AQ39651462-20202473-0E1F-4F8B-B804-10EB5AF71841Q40173243-B253ED47-0CF7-40A0-A4C3-6629AC23FAF0Q43011767-3BBD23AB-DFCB-4A88-8B62-3B56E80F6973Q46462494-B3D6B63F-C3D1-45FE-B46D-E8B32ABB4A4F
P2860
Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Antiretroviral therapy during ...... challenge in rhesus macaques.
@ast
Antiretroviral therapy during ...... challenge in rhesus macaques.
@en
type
label
Antiretroviral therapy during ...... challenge in rhesus macaques.
@ast
Antiretroviral therapy during ...... challenge in rhesus macaques.
@en
prefLabel
Antiretroviral therapy during ...... challenge in rhesus macaques.
@ast
Antiretroviral therapy during ...... challenge in rhesus macaques.
@en
P2093
P2860
P1433
P1476
Antiretroviral therapy during ...... s challenge in rhesus macaques
@en
P2093
B Rosenwirth
I G Nieuwenhuis
N Bischofberger
P ten Haaft
W M Bogers
P2860
P304
P356
10.1128/JVI.74.4.1704-1711.2000
P577
2000-02-01T00:00:00Z